Sandra Horning, MD, Joins Gilead Sciences’ Board of Directors
January 30 2020 - 4:05PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Sandra
Horning, MD, has been appointed to the company’s Board of
Directors.
Dr. Horning retired in 2019 as Chief Medical Officer and Global
Head of Product Development for Roche, after a 10-year career at
Roche and Genentech during which she helped bring 15 new medicines
to patients in disease areas including cancer, multiple sclerosis,
influenza and blindness. Prior to her career at Roche, Dr. Horning
spent 25 years as a practicing oncologist, investigator and tenured
professor at Stanford University School of Medicine. From 2015 to
2018, Dr. Horning served on the Foundation Medicine Board of
Directors and she currently serves as an advisor to EQRx.
“We are very pleased to welcome Sandra Horning to our Board of
Directors,” said Daniel O’Day, Chairman and Chief Executive Officer
of Gilead Sciences. “Sandra has significant industry expertise and
vast experience in drug development across multiple therapeutic
areas. In addition, she brings the perspective of a leading
physician who has spent more than two decades caring for patients
with cancer. Sandra’s presence on our Board will be a tremendous
asset as we enter the next chapter for Gilead with the goal of
rapidly advancing new, transformative medicines.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200130005774/en/
Douglas Maffei, Investors (650) 522-2739
Amy Flood, Media (650) 522-5643
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024